The HPV testing landscape: Hybrid Capture^® technology versus other HPV– testing methods

The Digene^® HPV Test* represents a significant improvement over existing technologies because of its sensitivity and objective results. The hc2 technology is used for the only FDA–approved diagnostic test for HPV DNA, combining the sophistication of nucleic acid detection technology with the simplicity of an immunoassay.

HPV Testing: A Clinical and Laboratory Value Comparison

HPV Testing: A Clinical and Laboratory Value Comparison
	hc2 Hybrid Capture	PCR Polymerase Chain Reaction	ISH In–Situ Hybridization
FDA–approved for primary adjunctive screening in women 30 and older	•
FDA–approved for ASC–US reflex testing	•
FDA–approved for testing from liquid cytology specimens*	•
Standardized procedure	•		•
Established, standardized clinical performance	•
Reports objective results	•	•
Detects the 13 clinically relevant high–risk types	•	Depends on method
Performance optimized for risk assessment and effective screening programs	•
Acknowledged in clinical guidelines	•
Abundant supporting data	•
Simple training and user validation	•
Simplified laboratory implementation	•
Quality controls provided	•
High throughput	•
Test for CT and GC from same specimen**	•

* FDA–approved for testing converted ThinPrep^® PreservCyt specimens type **Using only Digene's STM collection media

back to top